Pressmeddelande

BioStock: Last patient dosed in Respiratorius’ PK study with VAL001

Cision Publicerad: 05 Jul 2022 08:32

Respiratorius finished June with good news announcing that the last patient had been dosed in the pharmacokinetic study with VAL001. The drug candidate against diffuse large B-cell lymphoma , VAL001, has undergone a clinical study to evaluate the tailor-made release profile before a phase III study can be initiated. BioStock took the opportunity to ask CEO Johan Drott a few of questions.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/last-patient-dosed-in-respiratorius-pk-study-with-val001/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om Respiratorius

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!